Abstract
Erenumab is a calcitonin gene-related peptide receptor antagonist monoclonal antibody indicated for migraine prophylaxis in treatment resistant patients first approved in 2018. In the pivotal trials, the only reported cutaneous adverse effect was injection site pain. Here, we report a 40-year-old Caucasian woman who presented with a polymorphic eruption of the extremities and trunk that initially presented in the days following her first injection of erenumab. The eruption was urticarial on the trunk and papulosquamous on the extremities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
